治疗非酒精性脂肪性肝病的调节代谢类药物临床试验研究进展  

Progress in clinical trials of metabolism regulators for treatment of nonalcoholic fatty liver disease

作　　者：刘玉硕 马申 轩秋慧 陈文斌 唐辉 高聆 LIU Yu-shuo;MA Shen;XUAN Qiu-hui;CHEN Wen-bin;TANG Hui;GAO Ling(Department of Endocrinology,Shandong Provincial Hospital Affiliated to Shandong First Medical University,Jinan 250021,China;Shandong Provincial Key Laboratory of Endocrinology and Lipid Metabolism,Jinan 250021,China;Institute of Endocrinology and Lipid Metabolism,Shandong Academy of Clinical Medicine,Jinan 250021,China;Stem Cell Clinical Research Center,Shandong Provincial Hospital Affiliated to Shandong First Medical University,Jinan 250021,China)

机构地区：[1]山东第一医科大学附属省立医院内分泌科,济南250021 [2]山东省内分泌与脂代谢重点实验室,济南250021 [3]山东省临床医学研究院内分泌代谢研究所,济南250021 [4]山东第一医科大学附属省立医院干细胞临床研究中心,济南250021

出　　处：《中国新药杂志》2022年第16期1584-1594,共11页Chinese Journal of New Drugs

基　　金：国家自然基金资助项目(91957209,82102372)。

摘　　要：非酒精性脂肪性肝病(NAFLD)是一种慢性疾病,全球患病率高达25%。由于该病的发病机制复杂,到目前为止尚无特效药治疗。大多数NAFLD新药是通过作用于某一靶点调节糖脂代谢改善症状,进而阻止非酒精性脂肪性肝炎(NASH)甚至肝硬化等更严重疾病的发生。本文通过检索美国临床试验注册中心(https://clinicaltrials.gov/)、中国临床试验注册中心(https://www.chictr.org.cn/)及药物临床登记与信息公示平台(http://www.chinadrugtrials.org.cn/),就作用于法尼醇X受体(FXR)、过氧化物酶体增殖物激活受体(PPARs)及胰高血糖素样肽-1(GLP-1)这3类受体的调节代谢类候选药物的临床注册试验进行综述,期望为非酒精性脂肪性肝病的临床治疗提供循证依据。Nonalcoholic fatty liver disease(NAFLD)is a chronic disease with a global prevalence of 25%.Due to its complex pathogenesis,there is no specific drug treatment so far.Most new drugs for NAFLD regulate glucose and lipid metabolism to improve symptoms by acting on a certain target to prevent the occurrence of more serious diseases such as Nash and even liver cirrhosis.By searching the website of clinicaltrials.gov,chictr.org.cn and chinadrugtrials.org.cn,this paper reviewed the clinical registration trials of candidate metabolism regulators acting on farnesoid X receptor(FXR),peroxisome proliferators-activated receptors(PPARs)and glucagon-like peptide-1(GLP-1)receptors,hoping to provide evidence-based basis for the clinical treatment of nonalcoholic fatty liver disease.

关 键 词：非酒精性脂肪性肝病 调节代谢类药物 法尼醇X受体 过氧化物酶体增殖物激活受体 胰高血糖素样肽-1 临床注册试验 

分 类 号：R969.4[医药卫生—药理学]